/AQST

AQST Stock - Aquestive Therapeutics, Inc.

Q: What is the analyst price target for AQST?

Analyst price target information is not currently available for AQST.

Q: What is AQST's market cap?

Market capitalization information is not currently available for AQST.

Healthcare|Drug Manufacturers - Specialty & Generic|NASDAQ

$3.42-2.56%

$0.09 (-2.56%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+177.8%upside

Target: $9.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AQST

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.66

52W High$7.55

52W Low$2.12

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$57.56M	$50.58M	$47.68M	$50.83M	$45.85M
Gross Profit	$39.69M	$29.75M	$28.29M	$35.84M	$32.88M
Gross Margin	69.0%	58.8%	59.3%	70.5%	71.7%
Operating Income	$-30,771,000	$-15,102,000	$-42,066,000	$-34,679,000	$-42,893,000
Net Income	$-44,137,000	$-7,870,000	$-54,410,000	$-70,539,000	$-55,783,000
Net Margin	-76.7%	-15.6%	-114.1%	-138.8%	-121.7%
EPS	$-0.51	$-0.13	$-1.12	$-1.85	$-1.66

Company Overview

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Visit Website

Earnings History & Surprises

AQST

Beat Rate

56%

Last 18 quarters

Avg Surprise

+12.0%

EPS vs Estimate

Beats / Misses

10/8

Last 12 quarters

Latest EPS

$-0.14

Q4 2025

EPS Surprise History

Q1 24

-50.0%

$-0.12vs$-0.08

Q2 24

-88.9%

$-0.17vs$-0.09

Q3 24

+72.7%

$-0.03vs$-0.11

Q4 24

-8.3%

$-0.13vs$-0.12

Q1 25

-35.7%

$-0.19vs$-0.14

Q2 25

-41.2%

$-0.24vs$-0.17

Q3 25

+22.2%

$-0.14vs$-0.18

Q4 25

-27.3%

$-0.14vs$-0.11

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 11, 2026	—	—	—	—
Q1 2026	Mar 4, 2026	$-0.14	—	—	—
Q4 2025	Nov 5, 2025	$-0.11	$-0.14	-27.3%	✗ MISS
Q3 2025	Aug 11, 2025	$-0.18	$-0.14	+22.2%	✓ BEAT
Q2 2025	May 12, 2025	$-0.17	$-0.24	-41.2%	✗ MISS
Q1 2025	Mar 5, 2025	$-0.14	$-0.19	-35.7%	✗ MISS
Q4 2024	Nov 4, 2024	$-0.12	$-0.13	-8.3%	✗ MISS
Q3 2024	Aug 6, 2024	$-0.11	$-0.03	+72.7%	✓ BEAT
Q2 2024	May 7, 2024	$-0.09	$-0.17	-88.9%	✗ MISS
Q1 2024	Mar 5, 2024	$-0.08	$-0.12	-50.0%	✗ MISS
Q4 2023	Nov 6, 2023	$-0.11	$-0.03	+72.7%	✓ BEAT
Q3 2023	Aug 7, 2023	$-0.11	$-0.10	+9.1%	✓ BEAT
Q2 2023	May 2, 2023	$-0.10	$0.11	+210.0%	✓ BEAT
Q1 2023	Mar 7, 2023	$-0.21	$-0.23	-9.5%	✗ MISS
Q4 2022	Nov 1, 2022	$-0.30	$-0.23	+23.3%	✓ BEAT
Q3 2022	Aug 2, 2022	$-0.41	$-0.36	+12.2%	✓ BEAT
Q2 2022	May 3, 2022	$-0.45	$-0.32	+28.9%	✓ BEAT
Q1 2022	Mar 8, 2022	$-0.37	$-0.38	-2.7%	✗ MISS
Q4 2021	Nov 2, 2021	$-0.40	$-0.37	+7.5%	✓ BEAT
Q3 2021	Aug 3, 2021	$-0.42	$-0.33	+21.4%	✓ BEAT

Frequently Asked Questions about AQST

What is AQST's current stock price?

Aquestive Therapeutics, Inc. (AQST) is currently trading at $3.42 per share. The stock has moved -2.56% today.

What is the analyst price target for AQST?

The average analyst price target for AQST is $9.50, based on 1 analyst.

What sector is Aquestive Therapeutics, Inc. in?

Aquestive Therapeutics, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.

What is AQST's market cap?

Aquestive Therapeutics, Inc. has a market capitalization of $0.34 billion, making it a small-cap company.

Does AQST pay dividends?

No, Aquestive Therapeutics, Inc. does not currently pay a dividend to shareholders.